Search Results
Jul 20, 2026, 10:31 ET Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-β1 Expression, and Others | DelveInsight
regenerative strategies is currently under investigation, including allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) from Citospin, STRO-3⁺ mesenchymal precursor cells (MPCs) from Mesoblast, autologous disc-derived cells such as BRTX-100, induced pluripotent stem cell (iPSC)-derived
More news about: DelveInsight Business Research, LLP
Jan 13, 2026, 10:01 ET The 3rd Annual Newark Summit for Real Estate, Economic Development & Placemaking Returns February 9th
CapitalJennifer Carillo-Perez, Partner, Connell FoleyElnardo Webster, Partner, Connell FoleyElias Millstein, Principal, The STRO CompaniesAngelo Genova, Esq., Co-Founder & Chairman, Genova BurnsMatthew Kertz, Partner, Genova Burns LLCFrank Ferruggia,
More news about: The Newark Summit by roundtable&advisory
Dec 19, 2025, 07:55 ET Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
simultaneously, benefiting GT Biopharma, Inc. (NASDAQ: GTBP), ADC Therapeutics SA (NYSE: ADCT), Sutro Biopharma, Inc. (NASDAQ: STRO), Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), and TScan Therapeutics, Inc. (NADSAQ: TCRX).
More news about: Equity Insider